Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan

BACKGROUND: The evolution of drug resistance is one of the biggest challenges in leishmaniasis and has prompted the need for new antileishmanial drugs. Repurposing of approved drugs is a faster and very attractive strategy that is gaining supporters worldwide. Different anticancer topoisomerase 1B (...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa-Teijeiro, Chloé, Wagner, Victoria, Corbeil, Audrey, d’Annessa, Ilda, Leprohon, Philippe, do Monte-Neto, Rubens L., Fernandez-Prada, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399852/
https://www.ncbi.nlm.nih.gov/pubmed/34454601
http://dx.doi.org/10.1186/s13071-021-04947-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399852/
https://www.ncbi.nlm.nih.gov/pubmed/34454601
http://dx.doi.org/10.1186/s13071-021-04947-4

Ejemplares similares